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Resection, Including Transplantation, for Hepatoblastoma and 
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Thomas E. Starzl, and Eugene S. Wiener 
Pittsburgh, Pennsylvania 
• long-term survival in children with primary hepatic 
malignancies can not be expected without complete tumor 
re.ection. In the last ten years we have treated 21 children 
with hepatocellular carcinoma tHCC) and 21 children with 
hepatoblastoma IHEP), with tumor extirpation our surgical 
goal. Operative treatment included partial hepatectomy HPH] 
20), either primary 110) or delayed (following chemotherapy) 
(10), total hepatectomy and orthotopic liver transplantation 
([OlT] 13), or upper abdominal exenteration and multiple 
organ transplantation (2). Two patients had both PH and 
subsequent total hepatectomy and Ol T. Overall survival was 
48% (20/42), with 9 patients dying of progressive disease 
prior to removal of their tumor. HEP patient survival was 61% 
(14/211. including 2 of 6 who underwent primary PH, 1 of 8 
who had delayed PH, and 5 of 6 who underwent Ol T. 
Survival for the children with HCC was 29% (6/211, including 
1 of 4 after primary PH. 1 of 2 following delayed PH, 3 of 1 
following Ol T, and 1 of 2 after exenteration and multiple 
organ transplantation. Preoperative chemotherapy facili-
tated removal of 10 initially unresectable tumors {8 HEP. 2 
HCC) at a second-look procedure. Total hepatectomy and 
OlT markedly improved survival in patients with disease 
unresectable by standard methods. Partial hepatectomy, 
either primary or delayed, should be attempted in all children 
with hepatic malignancies. Total hepatectomy and OlT ap-
pears to be a viable adjunct in the treatment of childhood 
malignancies, and should be used for otherwise unre.ectable 
tumors as part of a carefully planned protocol. 
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CHILDHOOD liver tumors continue to have a poor prognosis despite increasingly sophisti-
cated diagnostic methods, aggressive surgical tech-
niques to achieve complete resection, and more 
effective systemic chemotherapy. Total surgical re-
moval remains the mainstay of treatment, although 
there are rare reports of long-term survivors achieved 
with chemotherapy alone. Preoperative chemother-
apy has increased the number of patients undergoing 
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potentially curable resections. I However, a large pro-
portion of children, especially with hepatocellular 
carcinoma (HCC), are not resectable by standard 
methods. Total hepatectomy and orthotopic liver 
transplantation (OLT), the only alternative for unre-
sectable tumors, is still controversial due to the high 
incidence of tumor recurrence.1 
We have treated 42 children with HCC or hepato-
blastoma (HEP) in the last 10 years, many of whom 
were evaluated elsewhere and felt to be unresectable. 
A retrospective review of their treatment courses is 
the basis for this report. Tumor resection, either by 
partial hepatectomy (primary or delayed) or total 
hepatectomy and OLT, was accomplished whenever 
possible. 
MATERIALS AND METHODS 
Demographics 
Fifty-six children with primary liver tumors were evaluated and 
treated at Children's Hospital of Pittsburgh from 1980 to 1990: 
HEP (21), HCC (21), sarcoma (5), anaplastic tumor (1), and 
incidental HCC (8). Mean ages for the 21 HEP and 21 HCC 
patients were 3.2 ::t 0.8 years and 9.9 ::t 1.0 years, respectively 
(P < .(01). There were 24 boys and 18 girls. All but 5 of the 42 
patients presented with an abdominal mass. Associated diseases 
were common, especially in HCC: tyrosinemIa (4), hepatitis B (2), 
complex congenital heart disease (2), and neonatal hepatitis (1). 
Two patients with HEP had the Beckwith-Wiedemann syndrome. 
Laboratory 
Platelet counts averaged 775,OOO/mmJ and 359,000/mmJ for 
HEP and HCC, respectively (normal, 150,000/mmJ to 450,0001 
mml;p < .003). a-Fetoprotein was elevated in 180f21 (86%) HEP 
children and 11 of 17 (65%) with HCC (P = .26), ranging from 215 
to 4,528,000 ng/mL. Mean SGOT was 137 lUlL and 71 lUlL 
(normal, <50 lUlL) and gamma glutamyl transpeptidase was 241 
lUll and 113 lUll (normal, <44 lUll) in HCC and HEP 
children, respectively. Four HCC patients but no HEP children 
had bilirubins greater than 3 mgl dL (normal, < 1.2 mgl dL). 
Imaging Studies 
Computed tomography was used in 40 patients, ultrasound 
examination in 36 patients, and magnetic resonance imaging in 5 
patients. Hepatic angiography was performed in 14 children; 10 
were studied to determine resectability. Four patients underwent 
angiography for possible intraarterial chemotherapy: one child had 
a replaced left hepatic artery and intraarterial chemotherapy was 
not administered while the other three patients underwent two (2) 
or three (1) courses. 
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Staging 
Tumor stage was determined at initial diagnosis according to 
current Children's Cancer Study Group (CCSG)/Pediatric Oncol-
ogy Group (POG) Intergroup study protocol: stage I, complete 
resection; stage II, microscopic residual; stage III, gross residual or 
nodal involvement; stage IV, metastatic disease. Patients under-
went operative biopsy if they had not been staged elsewhere. 
Percutaneous needle biopsy was used in three patients with 
obvious metastatic disease. 
Transplantation 
Transplantation was performed an average of 6 months follow-
ing initial presentation. Immunosuppression included cyclosporine 
and prednisone in the first 9 patients and FK506 in the last 6. 
Thirteen patients underwent total hepatectomy and celiac/pyloric 
lymphadenectomy. Two patients underwent upper abdominal exen-
teration (cluster procedure): removal of their liver, pancreas, 
stomach, spleen, duodenum. and proximal jejunum.J OLT was 
performed in all children and the 2 cluster patients also had 
pancreatic islet cell transplantation. Islets were isolated from the 
donor pancreas, purified by a COBE 2991 cell separator (COBE 
Laboratories, Lakewood, CO), resuspended in Hank's solution 
with 10% albumin, and infused through the portal vein into the 
newly engrafted liver.' 
Chemotherapy 
Seven patients received adjuvant chemotherapy following com-
plete primary tumor resection. Thirty-five patients received chemo-
therapy to treat residual disease following initial resection (3) or 
biopsy (32). Most children were treated on CCSG protocols, in 
which Adriamycin and cisplatin predominate. Cytoxan, vincristine, 
bleomycin, 5-ftuorouracil (5-FU), and VP·16 were also used, 
particularly in treatment failures. Three transplant patients re-
ceived preoperative intraarterial infusion of Adriamycin and cispl-
atin conjugated with Lipiodol, ie, chemoembolization, followed by 
postoperative systemic 5-FU, folinic acid, and interferon. 
Statistics 
Descriptive analyses were by unpaired Student's t tests, with 
mean ::!: SEM. Distributions were compared using the X' test of 
proportions or Fisher's exact test where appropriate. P < 0.05 was 
considered significant. 
RESULTS 
Staging 
Results for HEP patients included: stage I (5), 
stage II (1), stage III (10), and stage IV (5). HCC 
staging included: stage I (2), stage II (2), stage III 
(12), and stage IV (5). Twenty-two patients (14 HCC 
and 8 HEP) were initially treated elsewhere and 
subsequently transferred, 20 of whom were felt unre-
sectable by the referring surgeons and 2 who had 
residual disease following resection. Of the 20 "in-
house" patients there were stage I (7), stage II (1) 
and stage III/IV (6 each). 
Pathology 
Seventeen of the 21 HEPs were classified into 
subtypes: mixed (8), epithelial (6: 2 fetal and 4 
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embryonal), teratoid (2), and anaplastic (1). There 
were three fibrolamellar variants and three cases of 
cirrhosis in the HCC patients. 
Initial Operation 
Ten patients (6 HEP, 4 HCe) underwent primary 
resection and 32 children had biopsy alone (29 
operative, 3 percutaneous) (Table 1). Estimated blood 
loss (EBL) for resections was 145 mL for HEP and 
4,000 mL for HCC patients (P < .05). Pathology 
confirmed negative margins in 5 of 6 HEP and 2 of 4 
HCC children. There was one HCC operative death 
following left lobectomy with a 10,OOO-mL EBL. Both 
HCC patients who underwent trisegmentectomy de-
veloped subphrenic abscesses, which progressed to an 
empyema and bronchopleural fistula in one, necessi-
tating a right lower lobectomy of the lung. There were 
no complications in the six primarily resected HEP 
patients. 
Second-Look Procedure 
Sixteen children (10 HEP, 6 HCe) had sufficient 
response to chemotherapy to warrant a second-look 
exploration an average of 5 months following diagno-
sis. Eight HEP patients underwent resection (EBL. 
1,100 mL), which included 6 trisegmentectomies, 
whereas only 2 HCC children could undergo resec-
tion (Table 1). Resection margins were negative for 
tumor in 9 of 10 patients (exception was HCC 
trisegmentectomy). One HEP patient suffered an 
intraoperative cardiac arrest from arrhythmia and 
subsequent death following right trisegmentectomy. 
One HCC patient and one HEP patient developed a 
biliary fistula that closed without operative interven-
tion and one HEP child experienced a wound infec-
tion. 
rable 1. Standard Hepatic Resections Performed,lncluding Both 
Primary and Delayed Procedures 
HEP 
Primary 
Resection (no.) 
Left lobectomy (2) 
Right lobectomy (2)* 
Right trisegmentectomy (1) 
Right anterior segmentec-
tomy(1) 
HCC 
Left lobectomy (2)* 
Right trisegmentectomy (2)* 
Delayed 
Resection (no.) 
Left lobectomy (1) 
Left trisegmentectomy (11 
Left lateral segmentectomy (1) 
Right trisegmentectomy (5) 
Right lobectomy (1) 
Right trisegmentectomy (1 )t 
Abbreviations: HEP. hepatOblastoma; HCC. hepatocellular carci-
noma. 
'One of the cases had margins of resection positive for tumor. 
tMargins of resection positive for tumor. 
: I 
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Transplantation 
Eighteen children underwent laparotomy for poten-
tial total hepatectomy and OLT. Three children had 
widespread intraabdominal metastases. Thirteen chil-
dren underwent total hepatectomy and OLT and 2 
children underwent the cluster procedure. Three 
children were returned to the operating room within 
48 hours of their transplant for bleeding (2) or 
suspected intestinal perforation (1). Eleven children 
experienced acute rejection episodes requiring immu-
nosupressive changes and one child required retrans-
plant for chronic rejection. Bacterial and viral infec-
tions were common: coagulase-negative staphylococcal 
bacteremia (3), cytomegalovirus hepatitis (2), respira-
tory syncytial virus (2), Candida peritonitis (1), and 
cryptosporidium (1). 
Survival 
Overall survival for HEP patients was 14 of 21 
(67%), with a follow-up of 2.4 ± 2.6 years (Table 2). 
Six HEP patients underwent primary resection: two 
died during adjuvant chemotherapy, one died of 
metastatic disease, and one required OLT for tumor 
recurrence. Thus, 2 of 6 (33%) patients are alive with 
no evidence of disease (NED) at 10.5 and 4.5 years 
following primary resection. Eight patients under-
went delayed resection~ 7 (87%) are alive with NED 
at 1.5 ± 1.1 years (P = .06 v primary resection). Two 
patients died of progressive disease having under-
gone biopsy alone. 
Overall survival for HCC was 6 of 21 (29%) 
(P < .05 v hepatoblastoma) (Table 2). Four children 
underwent primary excision: one is alive (7.5 years). 
Two children underwent delayed resection: one is 
alive with NED (3.2 years) and the other died 
following OLT and subsequent tumor recurrence. 
Seven patients died of progressive disease prior to 
tumor resection. 
Nine of 15 (60%) transplanted children are pres-
ently alive with NED (1.9 ± 0.5 years), including 5 of 
Table 2. Overall Treatment Results for Hepatoblanoma and 
Hepatocellular Carcinoma Patients 
Overall Primary Deleyed 
Survival Resection Resection OLT Cluster Biopsy 
HEP 14/21* 21St 7/8 5/S 0/2 
(S7%) (33%' (87%) (83%1 (0%) 
HCC 6/21* 1/4 1/2* 3/7 1/2 0/7 
(29%) (25%) (50%) (44%) (50%) (0%) 
Abbreviations.: HEP. hepall;lblastoma; HCC. hepatocellular carci-
noma; OL T, total hepatectomy and orthotopic liver transplantation. 
'p < .05. 
tOne ofthe two survivors 'is status post OLT. 
*The child who died ,diG! so fQllolidag lUaIOr cacurrence. OL T, and 
subsequent tumor re-recu~ 
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Table 3. Prognostic Factors Aseociated WIth Tumor Recurre_ and 
Survival Following Transplantation 
Cue Vascular Lymph Follow-Up 
No, Invuion Node MBtII Outcome" (mol 
HEP 1 + Alive 5 
2 + + + Dead 
3 + Alive 13 
4 + + + Alive 3S 
HCC 1 + + Dead S 
2 + Dead 30 
3 + Alive 32 
4 + + Dead 14 
5 + + Alive 13 
6 + Dead 7 
Abbreviations: HEP. hepatoblastoma; HCC, hepatocellular carci-
noma; Mets, intraabdominal metastases. 
"None of the patients wIlD are alive have recurrent disease. 
6 (83%) HEP children (1.3 ± 0.9 years) and 4 of 9 
(44%) HCC children (2.3 ± 1.2 years). One child who 
underwent a cluster procedure for HCC is alive with 
NED (off all exogenous insulin) at 14 months post-
transplant. All six transplant deaths were due to 
malignancy. One HCC child died of severe lymphopro-
liferative disease (Burkitt's lymphoma) 8 years post-
transplantation. The remaining five deaths were sec-
ondary to recurrence of the initial tumor in the 
transplanted liver (1), distant site (3), or both (1). 
Prognostic factors for recurrence (vascular invasion, 
lymph node involvement, intraabdominal metastases) 
were evaluated in all transplant patients. Four of six 
HEP patients had at least one poor prognostic factor, 
but three of those four are alive with NED. Six of nine 
HCC patients had at least one factor present, and two 
of those six are presently alive with NED (Table 3). 
Chemotherapy 
Three of seven children (43%) who received adju-
vant chemotherapy following primary tumor resec-
tion survived. Preoperative chemotherapy converted 
10 of 32 (31%) initially unresectable tumors (8/15 
HEP, 2/17 HCC) to removable at a second-look 
procedure; only one (HCC) had a positive margin for 
tumor. Three deaths were directly attributable to 
chemotherapy. Two children died of sepsis during a 
pancytopenic period while receiving adjuvant ther-
apy. One child died as the result of an intraoperative 
cardiac arrhythmia ascribed to Adriamycin toxicity 
and another child developed nonlethal Adriamycin 
cardiotoxicity. Restrictive lung disease developed in 
one patient following bleomycin therapy. 
All children developed nausea and vomiting follow-
ing chemoembolization; one also had significant el-
evation of her liver transaminases. There were no 
technical complications related to angiography for 
chemoembolization. 
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DISCUSSION 
In their classic 1967 monograph Ishak and Glunz 
were the first to classify childhood epithelial liver 
neoplasms into hepatoblastoma and hepatocarci-
noma.s They reviewed 47 such cases from the Armed 
Forces Institute of Pathology, reporting that 0 of 12 
HCC children and 10 of 35 (29%) HEP patients 
survived. They particularly noted that 9 of 10 (90%) 
of the survivors had undergone resection. Subse-
quently, a 1974 survey of the Surgical Section of the 
American Academy of Pediatrics reported survival 
rates of 35% (45/129) for HEP and 13% (12/98) for 
HCC.6 Importantly, no HCC or HEP patient survived 
who did not undergo resection. Thus, it became 
apparent that resection was required to cure malig-
nant liver tumors in children. 
However. primary standard hepatic resection is 
feasible only in a minority of patients.7 Various 
surgical techniques have been used to increase the 
percentage of resectable tumors: profound hypother-
mia and circulatory arrest,S hemodilutional anesthe-
sia,9 total hepatic vascular exclusion,lO and concomi-
tant liver and inferior vena cava resection. 11 However, 
none of these techniques have reliably increased the 
number of liver tumors amenable to partial hepatec-
tomy. Efforts using chemotherapy to increase the 
percentage of children able to undergo resection 
were not initially encouraging.s It wasn't until 1982, 
when Evans et al12 reported the results of a coopera-
tive CCSG and Southwest Oncology Group (SWOG) 
study, that combination chemotherapy was shown to 
affect a significant percentage (12/27) of unresect-
able liver malignancies. In that same year, Weinblatt 
et aP3 reported that 7 of 8 (87%) unresectable 
childhood hepatic malignancies treated with chemo-
therapy exhibited a pronounced clinical response; 
four HEP children were able to have complete 
surgical excision of residual disease and one HCC 
patient had complete disappearance of all disease 
without surgery. More recently, continuous-infusion 
Adriamycin and cisplatin facilitated delayed hepatic 
resection in 20 of 34 (59%) initially unresectable liver 
tumors. 1 In the present series preoperative chemother-
apy facilitated removal of 8 of 15 HEP but only 2 of 17 
HCC tumors (one with positive margins) by delayed 
resection. 
The present data also indicated that those patients 
with HEP undergoing primary resection fared worse 
(2/6 NED) than those who underwent initial biopsy, 
chemotherapy, and second-look procedure (7/8 
NED), although follow-up lengths were not compara-
ble. A similar result was also seen at Children's 
Hospital of Los Angeles, where mean and 2-year 
survival for initially resected tumors were 23 months 
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and 37.5%, respectively, versus 4 years and 100% for 
those initially undergoing chemotherapy.14 However, 
this has not been a universal finding, and in the 
CCSG IPOG experience, survival following delayed 
resection and primary resection was 41% and 58%, 
respectively. 1 
This apparent improvement in survival by delayed 
resection has been accompanied by a definite in-
crease in operative morbidity. In our series, EBL for 
primary versus delayed HEP resection of was 143 mL 
versus 1,100 mL (P < .05). Similarly, there was one 
intraoperative death, one biliary fistula, and one 
wound infection in the eight HEP patients undergo-
ing delayed resection, whereas there were no compli-
cations in the six children who were primarily resected. 
The recent CCSG/POG intergroup prospective study 
reported similar findings, with morbidity rates of 8% 
and 25% for primary and delayed resection. 1 
Partial hepatectomy, either primary or delayed, 
was considered first for all patients in this series. 
Twenty patients were initially evaluated elsewhere, 
felt to be unresectable, and were then referred for 
OLT. Our transplant team, which has one of the 
world's largest experiences with partial hepatic resec-
tion,Is performed partial hepatectomies whenever 
possible. However, because overall resectability rates 
for primary liver malignancies rarely exceed 30% to 
40%, total hepatectomy and liver replacement is a 
logical alternative to achieve complete resection. I6 
Total hepatectomy and OLT was used only when 
standard resection was not possible. 
The data cautiously support the role of transplanta-
tion in pediatric hepatic malignancies. Five of 6 
(83%) patients transplanted for HEP are presently 
alive with NED (1.3 years). Four of 9 children (44%) 
with HCC are presently alive and NED (2.3 years), 
including a 15-year-old girl who is over 1 year postop-
eration from upper abdominal exenteration, OLT, 
and islet cell transplantation. Obviously, longer fol-
low-up periods will be required before this optimism 
can be substantiated, but a recent lO-institution 
report on 12 children who underwent OL T for HEP 
found 50% survival at 24 to 70 months without 
recurrence.17 
Many of the early successes in liver transplantation 
were obtained in patients with hepatic tumors. How-
ever, the tumors frequently recurred, often in the first 
2 years. In 1985, Iwatsuki et al reported tumor 
recurrence in 5 of 6 (83%) children who received liver 
replacement for unresectable hepatic malignancies. IS 
Israel Penn, in a recent review of the Cincinnati 
(previously Denver) Transplant Tumor Registry, eval-
uated overall recurrence rates and 2- and 5-year 
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tumor-free survivals in 597 patients (both adult and 
children) transplanted for hepatic malignancies.2 Best 
results were seen in incidental hepatoma (15% recur-
rence, 21% and 11% 2- and 5-year follow-up), HEP 
(40%,32%, and 7%, respectively), and fibrolamellar 
hepatoma (42%, 32%, and 6%, respectively). HCC 
had a 41 % recurrence with 2- and 5-year survivals of 
7% and 3%. 
Factors that help predict tumor recurrence are 
poorly understood at the present time. Ringe et al,19 
in a retrospective analysis of 95 patients transplanted 
for malignancy, found a better prognosis in earlier 
disease stages and in recipients without lymph node 
involvement. Iwatsuki et al found similar results in 
HCC patients; vascular invasion, tumor number, 
tumor shape, and lymph node invasion were found to 
be significant independent factors affecting survival.20 
However, in a review of 28 patients transplanted for 
hepatic malignancies (primary and metastatic) at 
UCLA. no specific prognostic factors correlating with 
survival or recurrence could be elucidated.21 Adult 
patients made up the vast majority of cases in those 
three reports, and there are little data on children 
transplanted for hepatic malignancies. Of our 15 
transplanted children, 10 (4 HEP and 6 HCC) had at 
TAGGE ET AL 
least one of the proposed prognostic factors for tumor 
recurrence. Five of those 10 are currently alive with 
NED, from 5 to 36 months posttransplant. Included 
in the survivors are a 2-year-old child who had 
omental involvement and vascular invasion (fol-
low-up 3 years) as well as several children who had 
tumor thrombus removed from their portal vein. 
Complete tumor extirpation remains the primary 
goal when treating pediatric hepatic malignancies. 
Primary resection, if done without excessive morbid-
ity and mortality, should be accomplished whenever 
possible. Preoperative chemotherapy has allowed 
resection for previously unresectable disease, particu-
larly in HEP patients. Although it is unclear whether 
primary resection offers superior survival rates to 
delayed resection, operative morbidity is increased in 
delayed procedures. Total hepatectomy and OLT 
improves survival in those who are unresectable 
following chemotherapy and is potentially a valuable 
adjunct in the treatment of childhood malignant liver 
tumors. However, due to the shortage of available 
donor organs and the unanswered questions regard-
ing tumor recurrence, OLT for hepatic malignancy 
should be performed only at transplant centers that 
use carefully planned protocols. 
REFERENCES 
1. King DR, Ortega J, Campbell J, et al: The surgical manage-
ment of children with incompletely resected hepatic cancer is facili-
tated by intensive chemotherapy. J Pediatr Surg 26: 1074-1081, 1991 
2. Penn I: Hepatic transplantation for primary and metastatic 
cancers of the liver. Surgery 110:726-738, 1991 
3. Stanl TE, Toko S, Tzakis A. et al: Abdominal organ cluster 
transplantation for the treatment of upper abdominal malignan-
cies. Ann Surg 210:374-386, 1989 
4. Tzakis AG. Ricordi C, Alejandro R. et al: Pancreatic islet 
transplantation after upper abdominal exenteration and liver 
replacement. Lancet 336:402-405. 1990 
5. Ishak KG. Glunz PR: Hepatoblastoma and hepatocarcinoma 
in infancy and childhood: report of 47 cases. Cancer 20:396-422, 
1967 
6. Exelby PR, Filler RM, Grosfeld JL: Liver tumors in children 
in the particular reference to hepatoblastoma and hepatocellular 
carcinoma: American Academy of Pediatrics Surgical Section 
survey-1974. J Pediatr Surg 10:329-337, 1975 
7. Giacomantonio M, Ein SH, Mancer K, et al: Thirty years of 
experience with pediatric primary malignant liver tumors. J Pediatr 
Surg 19:523-526,1984 
8. Ein SH, Shandling B, Williams WG, et al: Major hepatic 
tumor resection using profound hypothermia and circulatory ar-
rest. J Pediatr Surg 16:339-342, 1981 
9. Schaller RT, Schaller J. Furman EB: The advantages of 
hemodilutional anesthesia for major liver resection in children. J 
Pediatr Surg 19:705-710, 1984 
10. Delva E, Nordlinger B, Parc R, et al: Hepatic vascular 
exclusion (HVE) for major liver resections. Int Surg 72:78-81, 1987 
11. Takayama T, Matkuuchi M, Kosuge T, et al: A hepatoblas-
toma originating in the caudate lobe radically resected with the 
inferior vena cava. Surgery 109:208-213, 1990 
12. Evans AE, Land VJ, Newton WA, et al: Combination 
chemotherapy (vinCristine, adriamycin, cyclophosphamide and 
5-FU) in the treatment of children with malignant hepatoma. 
Cancer 50:821-826,1982 
13. Weinblatt MD, Siegel SE, Siegel MM, et al: Pre-operative 
chemotherapy for unresectable primary hepatic malignancies in 
children. Cancer 50:1061-1064,1982 
14. Mahour GH, Wagu GU, Siegel SE, et al: Improved survival 
in infants and children with primary malignant liver tumors. Am J 
Surg 146:236-240, 1983 
15. Iwatsuki S, Stanl T: Experience with resection of primary 
hepatic malignancy. Surg Clin North Am 69:315-322, 1989 
16. Stanl TE, Koep U: Surgical approaches for primary and 
metastatic liver neoplasms, including total hepatectomy with ortho-
topic liver transplantation. Prog ain Cancer 7:181-193,1978 
17. Koneru B, FJye MW, Busuttil RW, et al: Liver transplanta-
tion for hepatoblastoma. The American experience. Ann Surg 
213:118-121,1991 
18. Iwatsuki S, Gordon RD, Shaw BW, et al: Role of liver 
transplantation in cancer therapy. Ann Surg 202:401-407,1985 
19. Ringe B, Wittekind C, Bechstein WO, et al: The role of liver 
transplantation in hepatobiliary malignancy. A retrospective analy-
sis of 95 patients with particular regard to tumor stage and 
recurrence. Ann Surg 209:88-98, 1989 
20. Iwatsuki S, Starzl TE, Yokoyama I, et al: Liver transplanta-
tion for hepatocellular carcinoma (hepatoma), in Abstracts of the 
IV Congress of the European Society for Organ Transplantation, 
1989, p41 
21. Olthoff K, Millis J, Rosove M, et al: Is liver transplantation 
justified for the treatment of hepatic malignancies? Arch Surg 
125:1261-1268, 1990 
TREATMENT OF PEDIATRIC LIVER TUMORS 297 
Discussion 
D.R. King (Columbus, OH): This is a very interest-
ing and provocative report and I just want to caution 
all of you to read the paper very carefully. You really 
have to dig into the paper to understand it well and I 
think that resection is the treatment for hepatoblas-
toma and hepatocellular carcinoma and transplant 
should be appropriately reserved for a few patients. I 
have some concern with the data. The overall survival 
for your stage I and II disease patients is 40%, 
whereas patients with stage III and IV disease had a 
50% survival. You did better with the worse patients. 
Can you explain that to me? The answer to me, for 
one reason, would be that the data are not mature. 
The majority of these patients seem to have been 
followed for less than 2 years and many of them may 
have been off chemotherapy for less than 6 to 12 
months. As an example, of the 15 children who 
underwent OLT there was a total follow-up of 28 
patient years. However, one of the survivors lived 7 
years, accounting for fully 25% of all the patient 
years, so that's a bit troublesome and to report these 
survivals as percentages when the follow-up has been 
so short may not be particularly meaningful. Do you 
have any survival curves that might help elucidate for 
us in a better statistical fashion what's happening to 
these patients? Were any of the OLT survivors 
patients who had incidental tumors? What were the 
selection criteria for orthotopic liver transplantation? 
Certainly the patient whose cr scan you showed 
seemed to have been a candidate for primary resec-
tion. It's interesting that surgical therapies seem to 
follow the interests of the organization. For instance, 
at Pittsburgh you've got a relatively low primary 
resection rate-25% as compared with 40% to 50% 
where those of us who don't do transplants perhaps 
might labor a little harder in the vineyard of resec-
tion. You also seem to have a low secondary resection 
rate in the CCSG study of continuous infusion. In 
other words, of the patients treated with chemother-
apy, 60% of them underwent a secondary resection 
successfully, whereas your resection rate was only a 
third. And it's interesting in the CCSG study of the 
continuous-infusion doxyrubicin, there was an overall 
46% survival at 29 months but this is only taking 
patients in stages II, III, and IV, whereas in this study 
the survival is about the same and includes a signifi-
cant percentage of patients with stage I disease. So, 
again, you and the institution are to be congratulated 
on a very successful transplant program but I think 
transplant needs to be kept in perspective and it is not 
treatment for these tumors, it is treatment for a small 
minority of these tumors. Perhaps for those with 
unresectable hepatocellular carcinoma, it could be 
considered more as a primary mode of therapy, which 
I think would be appropriate. 
Edward P. Tagge (response): I thank Dr King for his 
comments. We do agree that this is a preliminary 
report and that the data, particularly for the trans-
planted patients, are not mature. However, Saul Penn 
recently presented data of some 600 liver transplants 
done for malignancy at the Central Surgical Society. 
In his study recurrence of the primary tumor occurred 
within the first 2 years in the vast majority (85%) of 
patients. 
Regarding our resection rate, it is not as good as 
the CCSG study that was presented last year, but 
certainly is in line with many other reports concerning 
primary resection for hepatic malignancies. In addi-
tion, half of our patients were referred from other 
institutions with "unresectable" disease. Thus, there 
was a significant bias toward advanced stage disease, 
which I think may help explain why primary resection 
was not more frequently performed. 
These data did not include the 8 children with 
incidental tumors who have undergone liver transplan-
tation. All 8 are alive with no evidence of disease at 
the present time. 
Standard partial hepatic resection was the initial 
goal of both the pediatric surgery and transplant 
surgery services. Our transplant surgeons have one of 
the world's largest experiences with partial hepatecto-
mies and, thus, transplantation was not considered 
until the child was felt to be unresectable by standard 
methods. If the patient was unresectable aggressive 
chemotherapy, including chemoembolization, was 
used prior to and following total hepatectomy and 
orthotopic liver transplantation. 
